GlassScriptPhysician profile
Ethan Y Brovman
NPI 1376885442
$6,064.88
in general payments reported to CMS, 2019-2025
27 companies · $1,747 in 2025
The $1,747 reported for 2025 was more than what 96% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,716 · 2021: $28.82 · 2022: $42.36 · 2023: $495 · 2024: $2,035 · 2025: $1,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,805 · Travel and Lodging: $1,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,804.52 |
| Travel and Lodging | $1,473.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,479.19 | 2024-2025 | Amplatzer, Amplatzer Amulet, Amplatzer Talisman |
| Medtronic Vascular, INC. | $1,181.58 | 2020 | |
| Edwards Lifesciences Corporation | $533.74 | 2024-2025 | Evoque, Pascal |
| Ancora Heart, INC. | $519.99 | 2020 | |
| Pfizer INC. | $371.25 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $265.54 | 2020-2025 | Wainua, Farxiga |
| Boston Scientific Corporation | $222.28 | 2024-2025 | Watchman Access System, Sentinel |
| Alnylam Pharmaceuticals INC. | $192.72 | 2023-2025 | Onpattro, Amvuttra |
| Amgen INC. | $192.01 | 2023-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $159.16 | 2024-2025 | |
| Masimo Corporation | $155.17 | 2024 | Set and Rainbow Set |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.86 | 2023-2025 | Jardiance, Ofev |
| Abiomed | $104.65 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.10 | 2023-2024 | Lifevest |
| Daiichi Sankyo INC. | $76.23 | 2023-2024 | Injectafer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $68.07 | 2022-2023 | Ozempic |
| Regeneron Healthcare Solutions, INC. | $51.42 | 2024 | Evkeeza |
| E.R. Squibb & Sons, L.L.C. | $50.31 | 2024 | Eliquis |
| Kiniksa Pharmaceuticals, LTD. | $45.81 | 2022-2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $45.35 | 2024-2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $42.55 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $27.43 | 2025 | Opsumit |
| Cardiva Medical, INC. | $25.16 | 2025 | Optowire |
| Bridgebio Pharma, INC. | $19.31 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $17.38 | 2023 | Nexletol |
| Scpharmaceuticals INC. | $15.60 | 2025 | |
| Chiesi USA, INC. | $13.02 | 2023 | Kengreal, Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Brovman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.